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ABSTRACT
Objectives: To assess the incremental cost-effectiveness ratio
(ICER) of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors in
patients with non-ST elevation acute coronary syndrome
(NSTE-ACS) pretreated with aspirin and clopidogrel under-
going an early invasive treatment strategy.
Methods: Cost-effectiveness analysis and cost-utility analysis
were performed from a health-care system perspective, based
on a Markov model with a time horizon of the patient life
span. The risk of death and ischemic events was assessed
using the Thrombolysis in Myocardial Infarction (TIMI) risk
score. We compared three strategies: 1) routine upstream use
of a GPIIb/IIIa inhibitor to all patients before angiography, 2)
deferred selective use of abciximab in the catheterization
laboratory just before angioplasty, and 3) double antiplatelet
therapy without GPIIb/IIIa inhibitors. Both univariate sensi-
tivity analysis and second-order probabilistic microsimula-
tion were performed.
Results: In the base case (65 years old, TIMI score 3), strat-
egy A was the most effective, with an ICER of €15,150 per
quality-adjusted life-year gained. Strategy B was dominated
by a combination of strategies A and C. The ICER was very
sensitive to the age and baseline risk of the patient. According
to the widely accepted cost-effectiveness thresholds, strategy
A would be cost-effective only in patients with an intermedi-
ate to high TIMI score, especially within the younger age
groups. The probability that strategy A was cost-effective
under the base case was 91.2%.
Conclusions: The use of GPIIb/IIIa inhibitors upstream in
high-risk NSTE-ACS patients (TIMI score 3) pretreated
with aspirin and clopidogrel is cost-effective, particularly in
the younger age groups.
Keywords: acute coronary syndrome, clopidogrel, cost-
effectiveness, glycoprotein IIb/IIIa inhibitors.
Introduction
The use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors
reduce the risk of adverse cardiac events in high-risk
patients with non-ST elevation acute coronary syn-
drome (NSTE-ACS) managed with an early invasive
strategy [1,2]. Therefore, the current guidelines recom-
mend the use of GPIIb/IIIa inhibitors in these patients,
either upstream to all patients or selectively in the
catheterization laboratory just before angioplasty in
patients with suitable coronary lesions [3–6].
GIIb/IIIa inhibitors are currently given along with
clopidogrel and aspirin (triple antiplatelet therapy)
[3–5]. Nevertheless, the available economic evalua-
tions are based on randomized clinical trial studies that
compare the efﬁcacy of double antiplatelet therapy
(a GPIIb/IIIa inhibitor plus aspirin) versus aspirin.
Because clopidogrel has not been routinely used in
these trials, they do not inform about the incremental
efﬁcacy and safety of GPIIb/IIIa inhibitors in patients
pretreated with clopidogrel. Consequently, most of the
available economic evaluations do not represent the
current clinical practice [7].
Recently, several studies have provided new evi-
dence on the beneﬁts and risks of using GPIIb/IIIa
inhibitors in patients pretreated with clopidogrel
[8,9], whereas other studies have added important
information on the comparative advantages of selec-
tive and upstream strategies [10,11]. Therefore, a
new economic evaluation of the use of GPIIb/IIIa
inhibitors under current clinical conditions, which
combines the most recent clinical and economic
studies, is justiﬁed.
Methods
The aim of this study was to assess the effectiveness
and economic efﬁciency of GPIIb/IIIa inhibitors (either
upstream or selectively) added to aspirin and clopi-
dogrel, compared with aspirin and clopidogrel alone,
in NSTE-ACS patients who undergo an early invasive
treatment strategy. The study was performed from the
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Spanish public health care system perspective, with a
time horizon of the patient life span.
Data Inputs (Tables 1–3)
The main source of evidence about the comparative
effectiveness and safety of triple versus double anti-
platelet therapy was a recent systematic review and
meta-analysis [9] based on nine randomized controlled
trials. According to this review, the addition of GPIIb/
IIIa inhibitors reduced the risk of death or myocardial
infarction at 30 days in those trials that included
patients with NSTE-ACS (relative risk [RR] 0.67; 95%
conﬁdence interval [CI] 0.56–0.80) but not in studies
that excluded NSTE-ACS patients (RR 1.07; 95% CI
0.75–1.53) (P-test of interaction 0.0175).
Conversely, the evidence about the effectiveness of
routine upstream versus selective use of GPIIb/IIIa
inhibitors is less straightforward [10,11]. In the
ACUITY timing trial [11], the selective deferred strat-
egy was associated with a nonsigniﬁcant relative
increase of ischemic complications at 30 days (7.9%
vs. 7.1%; RR 1.12; 95% CI 0.97–1.29) and a statisti-
cally signiﬁcant reduction in major bleeding (6.1% vs.
4.9%; RR 0.80; 95% CI 0.67–0.95; P = 0.009). Unfor-
tunately, the ACUITY study did not inform about
long-term clinical outcomes; therefore, the long-term
effect of bleeding on future adverse cardiac events was
obtained from other sources [12].
Data of the health-care costs were obtained from
Spanish studies. The costs were adjusted for inﬂation
using the Spanish consumer price index and were
actualized to the year 2006 [13]. According to the per-
spective of the economic evaluation, the study only
considered direct health-care costs, and ignored indi-
rect costs (as the time of the patient and their atten-
dants), while intangible costs (related to the pain and
suffering of the patient) were included in the denomi-
nator of the cost-effectiveness, as part of the quality-
adjusted life-years (QALYs) [14].
The utilities associated with the different events and
health states were obtained from a nonsystematic
review of the literature. A number of data sources
provided useful estimated utilities associated with
coronary disease and bleeding complications. Never-
theless, none of these sources provided separate esti-
mates for all the relevant states based on consistent
valuation methods. Therefore, consensus among the
authors was used when appropriate. The sources of
data about the effectiveness, costs and utilities are sum-
marized in Tables 1–3 [1,7,9–12,15–26].
Decision Model
The study was based on a Markov model [27] that
compared three strategies for high-risk patients with
NSTE-ACS treated with aspirin and clopidogrel as
part of an early invasive strategy. Strategy A consisted
of the early administration (“upstream”) of a GPIIb/
IIIa inhibitor (tiroﬁban or epitiﬁbatide) to all the
patients before coronary angiography. Under strategy
B (“selective” strategy), the GPIIb/IIIa inhibitor (in
this case abciximab) was deferred for those patients
in which, after the performance of a coronary angio-
Table 1 Estimated probabilities and effect measures
Variable Basal value Rank Source
Mortality of old uncomplicated coronary syndrome 0.0765 0.05–0.09 Robinson et al. 2005 [7]
Mortality of old myocardial infarction 0.0734 0.05–0.09 Robinson et al. 2005 [7]
Late mortality caused by coronary artery disease 0.009 0.005–0.018 This article
Annual risk of nonfatal infarction in old previously uncomplicated coronary syndrome 0.02 0.01–0.04 Robinson et al. 2005 [7]
Absolute risk of events increase after an episode of major bleeding 0.2 0.05–0.3 Stone et al. 2007 [11]
Proportion of adverse cardiac events with death 0.186 0.09–0.28 Bosch and Marrugat 2001 [1]
Probability of percutaneous revascularization alters coronary angiography 0.55 0.4–0.8 Stone et al. 2007 [11]
Probability of coronary artery bypass graft after coronary angiography 0.27 0.10–0.40 Stone et al. 2007 [11]
Basal risk of major bleeding 0.015 0.01–0.03 Glaser et al. 2006 [10]
Basal risk of major bleeding after coronary artery bypass graft 0.05 0.01–0.1 Glaser et al. 2006 [10]
Basal risk of major bleeding after coronary angiography 0.02 0.01–0.04 Yusuf et al. 2006 [12],
Latour-Pérez et al. 2007 [9]
Relative risk (RR) of adverse cardiac events with clopidogrel 0.83 0.70–0.99 Mehta et al. 2001 [16]
RR of adverse cardiac events with GPIIb/IIIa inhibitors in patients treated with clopidogrel 0.67 0.56–0.80 Latour-Pérez et al. 2007 [9]
RR of major bleeding with clopidogrel 1.5 1–2 Mehta et al. 2001 [16],
Steinhubl et al. 2002 [17]
RR of major bleeding with triple vs. double antiplatelet therapy 1.4 1–2 Latour-Pérez et al. 2007 [9]
RR of major bleeding with upstream vs. selective administration of GPIIb/IIIa inhibitors 1.10 1.03–1.16 Stone et al. 2007 [11]
RR of death with acute myocardial infarction vs. old uncomplicated coronary syndrome 1.33 1–2 Mark et al. 2000 [19]
Risk of events during the ﬁrst year: — Antman et al. 2000 [15] and
projection of authors
TIMI score 0–1 0.034
TIMI score 2 0.043
TIMI score 3 0.077
TIMI score 4 0.119
TIMI score 5 0.152
TIMI score 6–7 0.191
GPIIb/IIIa, glycoprotein IIb/IIIa.
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graphy, it was decided to carry out an immediate
percutaneous revascularization procedure. In strategy
C (“reference comparison group”), the patients were
assumed to receive standard antiplatelet therapy
(aspirin + clopidogrel) without systematic administra-
tion of a GPIIb/IIIa inhibitor (bailout use is permitted).
Each one of these three strategies was included in a
decision tree as a Markov node, with annual cycles and
four possible states (Figs. 1 and 2): early acute coro-
nary syndrome (the ﬁrst year after the admission), late
coronary syndrome (patients without adverse cardiac
events after the ﬁrst year), postmyocardial infarction
(patients with myocardial infarction or reinfarction
after the admission), and death (the absorbent state).
Initially, all the patients begin the process with the
early acute coronary syndrome state. During the ﬁrst
year, the model considered the possibility of undergo-
ing some procedures (percutaneous revascularization,
aorto-coronary bypass graft) and adverse events
(major bleeding, recurrent ischemia, myocardial
infarction, or cardiac death). From beginning of
the second year on, the model considered simply the
possibility of age-related death (according to the
age-speciﬁc mortality rate of the Spanish population
during the year 2005 [28]) and the possibility of suf-
fering cardiac events (either fatal or nonfatal).
The model was analyzed in a recursive way, as
transitions between states. Each Markov state was
associated with different costs and utilities. During
each cycle, the patients stayed in a single state and
accumulated costs and utilities, depending on the spe-
ciﬁc Markov state. In addition to the costs and utilities
related to the permanence in a state, certain procedures
and events were “penalized” with extra costs (“tran-
sition costs”) and disutilities. Because a long time
horizon was considered, a discount rate was applied
for both costs and utilities (with a basal annual rate of
3%) [14].
The decision model presented certain peculiarities
and structural assumptions that should be highlighted.
First, the model assumed that the effect of the GPI-
IbIIIa inhibitors was restricted to the ﬁrst year; from
the second year on, the prognosis was entirely deter-
mined by the Markov state in which the patient was
located. It was also assumed that the short-term efﬁ-
cacy (RR) of small molecule GPIIb/IIIa inhibitors
(tiroﬁban or eptiﬁbatide) upstream was equivalent to
that of abciximab administered downstream, while the
upstream strategy was associated with a higher rate of
major bleeding [11]. Additionally, the model assumed
that the previous use of a GPIIb/IIIa inhibitor did not
modify the revascularization rates and that the relative
proportion of coronary events (death and nonfatal
myocardial infarction) remained constant in time and
independent of the applied therapeutic strategy.
The risk of adverse cardiac events during the ﬁrst
year depended on the baseline risk of the patient (as
measured by its TIMI risk score [15]) and the effec-
Table 2 Estimated costs
Variable Basal value Rank Source
Daily cost of clopidogrel 2.06 1.37–2.06 Sale prices (public/hospital)
Cost of upstream GPIIb/IIIa therapy 312 312–374 Sale prices (public/hospital)
Cost of downstream abciximab 781 781 Cequier et al. 2006 [20]
Daily cost of hospitalization in the cardiology ward 403 300–500 Cequier et al. 2006 [20]
Daily cost of hospitalization in the intensive care unit 1,238 600–1,700 Badia et al. 2005 [21]
Cost of percutaneous revascularization 1,710 1,000–2,000 Oliva et al. 2004 [22], Russell et al. 2006 [23]
Cost of coronary artery bypass graft 14,617 12,000–16,000 Russell et al. 2006 [23]
Cost of an episode of major bleeding 1,394 1,000–1,500 Cequier et al. 2006 [20]
Yearly medical costs of patient with old myocardial infarction 753 600–1,200 Badia et al. 2005 [21]
Cost of an adverse cardiac event 8,840 3,000–10,000 Badia et al. 2005 [21]
All the costs are in euros and are actualized to June of 2006.
GPIIb/IIIa, glycoprotein IIb/IIIa.
Table 3 Estimated utilities
Variable Basal value Rank Source
Utility of and old uncomplicated coronary syndrome 0.817 0.6–0.94 Robinson et al. 2005* [7]
Mark et al. 1995* [18]
Kuntz et al. 1996* [26], and this article†
Utility of an old myocardial infarction 0.80 0.6–0.94 Robinson et al. 2005 [7]
Mark et al. 1995* [18]
Kuntz et al. 1996* [26], and this article†
Utility of suffering an adverse cardiac event -0.1 -0.1–0 Kalish et al. 1995* [24]
Utility of suffering an episode of major bleeding -0.05 -0.1–0 Eckman et al. 1998† [25], and this article†
Utility of suffering a coronary artery bypass graft -0.1 -0.2–0 Kuntz et al. 1996* [26], and this article†
Utility of suffering percutaneous coronary revascularization -0.05 -0.1–0 Kuntz et al. 1996* [26], and this article†
*Time trade-off method.
†Expert criteria.
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tiveness (RR) of the therapeutic intervention consid-
ered. Because the original score [15] dealt with the
short-term prognosis, the risk of death or nonfatal
infarction during the ﬁrst year was estimated by
graphical extrapolation [19]. For example, if a patient
has a baseline risk of events in the ﬁrst year of 0.047
(corresponding approximately to a TIMI score of 3)
treated with clopidogrel (RR 0.83), the probability of
suffering a cardiac event during the ﬁrst year will be of
0.039 (0.047 ¥ 0.83). The model took into account the
increase of coronary events after one episode of
bleeding, probably related to the withdrawal of the
antiplatelet therapy and/or the development of a
pro-trombotic state [12,29].
The impact of the patient’s age was recognized in
the model by using two strategies. On the one hand,
the higher incidence of events during the ﬁrst year in
elderly patients was incorporated in the TIMI score
(age was one of the items). On the other hand, the
model analyzed separately the late mortality attribut-
able to age according to the age-speciﬁc mortality rate
for the Spanish population [28] and the late mortality
because of coronary artery disease [30].
Data Analysis
To validate the model, the survival observed in several
external cohorts [12,19,31–34] was compared with
the survival predicted by the model for similar levels of
age and baseline risk.
The analysis began with the estimation of the incre-
mental cost-effectiveness ratio (ICER) for a base case
(a 65-year-old patient with a TIMI score of 3, and the
remainder of the variables at the basal levels [Tables
1–3]). This base case represented approximately the
average patient included in the published cohort
studies [12,19,31–34]. The incremental cost per QALY
gained, cost per year of life gained, and cost per event
prevented were calculated. A basal discount rate was
applied to all the estimations.
To assess the uncertainty associated with the proba-
bilistic nature of the input variables, the probabilities,
costs, and utilities (with the exception of age, pharma-
ceutical prices, and days of hospitalization) were
entered into the model as triangular probability distri-
butions whose maximum is the basal value and the
limits are the rank of uncertainty utilized in the analy-
sis [35]. A one-way sensitivity analysis was performed
for each one of the variables included in the model.
Second, the joint effect of the main determinants of the
ICER, identiﬁed by the one-way sensitivity analysis
(age, TIMI score [15], and effectiveness of the anti-
platelet therapy), was examined in different scenarios.
Third, the simultaneous effect of all the variables (dis-
tributions) included in the model was analyzed using
Monte Carlo probabilistic sensitivity analysis [35].
This method yields a distribution of effectiveness and
cost values and permits the estimation of the probabil-
ity that the intervention is cost-effective for various
threshold values of the cost-effectiveness ratio.
All the analyses were performed using the commer-
cial software DATA-Pro version 11 (TreeAge Software
Inc., Williamstown, MA).
Results
The survival predicted by the Markov model was rea-
sonably comparable to that reported in diverse cohorts
of patients admitted with NSTE-ACS [12,19,31–34].
In comparison with strategy C (double antiplatelet
therapy), under the base case, by each 1000 patients
treated with strategy A (upstream GPIIB/IIIA inhibi-
tor) 16 adverse cardiac events would have been
avoided, with a cost per event avoided (discounted) of
€37,640. Depending on the basal risk, the cost per
avoided event ranked from €13,009 to €91,924 (for
patients with a TIMI of 6–7 and 0–1, respectively).
In terms of the expected survival, the adverse events
avoided with strategy A would be translated into a life
expectancy (discounted) 6 months higher that with
strategy C, with a cost per year of life gained of
€12,120.
In terms of utilities, the improvement was of 0.04
QALYs, with an incremental cost of €15,150 per
QALY gained thanks to the upstream use of a GPIIb/
IIIa inhibitor (Table 4). This estimation did not change
signiﬁcantly when the costs were adjusted using the
Spanish medical inﬂation index instead of the con-
sumer price index.
Strategy B was slightly less costly but was also less
effective than strategy A, with an incremental cost-







Figure 1 Markov states diagram. ACS, acute coronary syndrome; AMI,
acute myocardial infarction.
856 Latour-Pérez et al.
Figure 2 Decision tree. p1, probability of percutaneous revascularization after coronary angiography; p2, basal risk of major bleeding after coronary
angiography ¥ Relative risk (RR) of major bleeding with clopidogrel ¥ RR of major bleeding with triple versus double antiplatelet therapy; p3, basal risk of
major bleeding after coronary artery bypass graft ¥ RR of major bleeding with clopidogrel; p4, basal risk of major bleeding after coronary angiography ¥ RR
of major bleeding with clopidogrel; p5, risk of events during the ﬁrst year (according to TIMI score) ¥ RR of adverse cardiac events with clopidogrel ¥ RR
of adverse cardiac events with glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors in patients treated with clopidogrel + absolute risk of events increase after an
episode of major bleeding; p6, proportion of adverse cardiac events with death; p7, risk of events during the ﬁrst year (according to TIMI score) ¥ RR of
adverse cardiac events with clopidogrel ¥ RR of adverse cardiac events with GPIIb/IIIa inhibitors in patients treated with clopidogrel; p8, probability of
Coronary artery bypass graft after coronary angiography; p9, age-speciﬁc mortality rate during year 2005 (for basal age + Markov cycle number); p10, late
mortality because of coronary artery disease (total mortality - mortality due to age); p11, risk of late nonfatal myocardial infarction. #, complementary
probability (1 minus probability).
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vs. strategy C). This situation of extended dominance
[36] featured in every type of analysis (cost per QALY,
cost per year, and cost per event avoided) and for all
the levels of TIMI.
The sensitivity analysis identiﬁed three critical
determinants of the efﬁciency of the triple antiplatelet
therapy: the basal risk of events (TIMI score), the
incremental effectiveness of the GPIIb/IIIa inhibitor,
and the age of the patient (Table 5, Fig. 3). Combina-
tions of these three variables arranged some scenarios
with different cost-effectiveness. Indeed, costs per
QALY gained ranked between €3919 (for a 55-years-
old patient with a TIMI score of 6–7) and €53,570 (for
an 85-year-old patient with a scoring of 0–1). Accord-
ing to the commonly accepted willingness to pay, strat-
egy A was cost-effective in patients with TIMI score
equal to or higher than 3 (especially in young patients)
and was not cost-effective in patients with low TIMI
score (especially in the elderly).
According to the Monte Carlo simulation, the strat-
egy of the upstream GPIIb/IIIa inhibitor would be cost-
effective in 91.2% of the cases (Fig. 4). This percentage
varied from 26.0% for patients with TIMI 0 to 1 and
99.6% for patients with TIMI 6 to 7.
Discussion
To date, the available studies that analyze the cost-
effectiveness of GPIIb/IIIa inhibitors in NSTE-ACS
patients rely on placebo-controlled clinical trials
[10,19,37–40], which do not inform about the incre-
mental beneﬁts and risks of GPIIb/IIIa inhibitors.
Fortunately, some recent studies provide adequate evi-
dence on the efﬁcacy and safety of triple antiplatelet
therapy in these patients [8,9]. This evidence allows
the assessment of the efﬁciency of this therapy in
patients already treated with clopidogrel.
The results of the reference case analysis show that
the use of upstream GPIIb/IIIa inhibitors in medium-
to high-risk NSTE-ACS patients pretreated with clopi-
dogrel who undergo an early invasive strategy, is
cost-effective according to the threshold recommended
for the adoption of health-care interventions in Spain
(€30.000 per saved life-year) [41]. As expected, the
ICER is attractive in patients with high TIMI score,
while it is unacceptable in patients with a TIMI score
lower than 3.
Although these data refer to the Spanish environ-
ment, the economic evaluations on clopidogrel [42,43]
and GPIIb/IIIa inhibitors [7,40] in NSTE-ACS patients
conducted in different countries provide results that
are remarkably similar. On the other hand, the sensi-
tivity analysis (Table 5) shows that the ICER of the
triple antiplatelet therapy in moderate- to high-risk
patients is beneath the commonly accepted boundary
of 50,000 dollars per QALY gained. This suggests that
the results of our study can be extrapolated to other
Western countries.
Current guidelines recommend administration of
GPIIb/IIIa inhibitors, either upstream to all high-risk
patients before angiography or deferred for selective
use in the catheterization laboratory just before angio-
plasty. Our study shows that, although the selective use
of abciximab is something less costly than strategy A
(upstream therapy with eptiﬁbatide or tiroﬁban), the
ICER of the selective strategy is higher. In other words,










A 21,599 37.12 12.73 10.33 15,150
B 21,440 37.80 12.71 10.31 22,350
C 20,993 38.73 12.68 10.29 –
A 3% discount rate is applied to all the estimates.
QALY, quality-adjusted life-year.




0–1 30,347 (20,943; 63,725) 44,621 (30,536; 95,534) 53,570 (36,517; 115,917)
2 22,377 (15,720; 44,068) 32,677 (22,761; 65,376) 39,105 (27,142; 78,851)
3 11,104 (7,973; 20,201) 15,918 (11,291; 29,430) 18,910 (13,355; 35,182)
4 6,736 (4,851; 11,984) 9,467 (6,689; 17,221) 11,167 (7,839; 20,475)
5 5,095 (3,659; 9,028) 7,049 (4,937; 12,848) 8,270 (5,741; 15,223)
6–7 3,919 (2,800; 6,952) 5,319 (3,673; 9,785) 6,199 (4,229; 11,548)
Figures between parentheses correspond to the predicted values for the 95% conﬁdence limits of the relative risk of the reduction of events because of the GPIIb/IIIa inhibitor
in patients previously treated with clopidogrel.
Because of the inherent variability of the method, the values cannot coincide exactly with the values predicted by the Monte Carlo simulation.
GPIIb/IIIa, glycoprotein IIb/IIIa.
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it is cheaper to gain a QALY with strategy A than with
strategy B. This situation of extended dominance [35]
means that, for a given closed budget, the overall
health results applying strategy B are worse than when
using strategy A for a speciﬁc segment of the popula-
tion and strategy C for the remainder.
As with most studies based on models, our eco-
nomic evaluation presents some limitations. First, the
model considers only three strategies and ignores other
alternatives (e.g., with bivalirudin [44,45] or fonda-
parinux [12]) that are recommended in the most
recently published guidelines [3,4].
Second, the long-term modeling compels us to make
some assumptions that are difﬁcult to demonstrate.
Nevertheless, the lifetime horizon should be long
enough to capture all relevant future effects of the
health-care intervention. Furthermore, survival pre-
dicted by the model is similar to the survival reported
in other cohort studies and economic evaluations
[12,19,31–34].
Third, data about probabilities, costs, and utilities
are sometimes sparse and of low quality, requiring best
guess estimates. Nevertheless, the sensitivity analysis
shows that most of these variables had a limited
impact on the output of the model, so the estimated
ICER was robust over a wide range of values of these
variables.
As counterpart, our study presents some strong
points that deserve to be mentioned. First, this study, in
contrast to others [10,19,38–40], used a comparison
strategy that combined treatment with aspirin and clo-
pidogrel, which is the currently relevant comparison,
not just aspirin. In addition, the decision tree incorpo-
rates some important aspects such as the impact of
increasing age and the effects of bleeding on the inci-
dence of major cardiac events and long-term mortality
[12].
Conclusion
We conclude that the use of GPIIb/IIIa inhibitors
upstream in high-risk NSTE-ACS patients pretreated
with aspirin and clopidogrel is cost-effective, particu-
larly in the younger age group.
We would like to thank Dr. Tim Dyke for his revision of the
paper.
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